Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94%…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
EverBridge Group and Cosmotec Forge Landmark Partnership
SHANGHAI, Sept. 15, 2025 /PRNewswire/ -- EverBridge Group announced an Exclusive Commercialization…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma…
Fermenta Board Approves Sale of Environmental Solutions Business to Wholly Owned Subsidiary
Strategic transfer to enhance operational focus and create dedicated environmental solutions platformTo…
EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts
PARIS, Sept. 17, 2025 /PRNewswire/ -- A new international study presented today…
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or…
Algernon Announces Preferred Share Class Approved at Annual and Special Meeting
VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the…
Herbalife India Launches New Episode of Its Flagship Podcast Featuring Dr. Shivangi Rana
'Live Your Best Life, Unscripted': A Deep Dive into Skincare, Science &…